Literature DB >> 15085067

Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart.

Petri Kaheinen1, Piero Pollesello, Jouko Levijoki, Heimo Haikala.   

Abstract

Levosimendan is a novel calcium sensitizer that increases contraction force without change in intracellular calcium ([Ca2+]i); milrinone is a phosphodiesterase inhibitor that exerts a positive inotropic effect by increasing [Ca2+]i. The effects of levosimendan and milrinone on oxygen consumption in the isolated guinea-pig heart were studied. Isolated guinea-pig hearts were paced (280 beats/min) and perfused according to the Langendorff technique. Levosimendan (0.01-1 microM) or milrinone (0.1-10 microM) were added cumulatively and changes from baseline for diastolic and systolic pressure (LVEDP and LVSP), contractility and relaxation (+dP/dt and -dP/dt), and coronary flow and oxygen consumption (CF and VO2) were calculated. Levosimendan was found to be 10 to 30 times more potent than milrinone as an inotropic agent. The effect on VO2 was markedly lower in levosimendan-perfused hearts than in milrinone-perfused hearts (P = 0.031 between the concentration-dependent effects of the two drugs). The maximum increase in VO2 was 10 +/- 4% in the levosimendan group and 38 +/- 15% in the milrinone group. The economy of the contraction was more advantageous in levosimendan-perfused hearts (P </= 0.005 vs. milrinone group on both VO2/+dP/dt and VO2/LVSP). It was concluded that levosimendan exerts a positive inotropic effect without disturbing the energy balance of the heart.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15085067     DOI: 10.1097/00005344-200404000-00011

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Integrative Methods for Studying Cardiac Energetics.

Authors:  Philippe Diolez; Véronique Deschodt-Arsac; Guillaume Calmettes; Gilles Gouspillou; Laurent Arsac; Pierre Jais; Michel Haissaguerre; Pierre Dos Santos
Journal:  Methods Mol Biol       Date:  2021

2.  Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failure.

Authors:  H W H van Hees; Gl Andrade Acuña; M Linkels; P N R Dekhuijzen; L M A Heunks
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 3.  What role does the right side of the heart play in circulation?

Authors:  Maurizio Cecconi; Edward Johnston; Andrew Rhodes
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

4.  Upscaling cardiac assist devices in decompensated heart failure: Choice of device and its timing.

Authors:  Sundeep Mishra
Journal:  Indian Heart J       Date:  2016-01-11

Review 5.  The Perspective of the Intensivist on Inotropes and Postoperative Care Following Pediatric Heart Surgery: An International Survey and Systematic Review of the Literature.

Authors:  Peter P Roeleveld; J C A de Klerk
Journal:  World J Pediatr Congenit Heart Surg       Date:  2017-11-01

Review 6.  Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; István Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo M A Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius G Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert H G Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  J Cardiovasc Pharmacol       Date:  2020-07       Impact factor: 3.105

Review 7.  Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.

Authors:  Zoltán Papp; Piergiuseppe Agostoni; Julian Alvarez; Dominique Bettex; Stefan Bouchez; Dulce Brito; Vladimir Černý; Josep Comin-Colet; Marisa G Crespo-Leiro; Juan F Delgado; Istvan Édes; Alexander A Eremenko; Dimitrios Farmakis; Francesco Fedele; Cândida Fonseca; Sonja Fruhwald; Massimo Girardis; Fabio Guarracino; Veli-Pekka Harjola; Matthias Heringlake; Antoine Herpain; Leo Ma Heunks; Tryggve Husebye; Višnja Ivancan; Kristjan Karason; Sundeep Kaul; Matti Kivikko; Janek Kubica; Josep Masip; Simon Matskeplishvili; Alexandre Mebazaa; Markku S Nieminen; Fabrizio Oliva; Julius-Gyula Papp; John Parissis; Alexander Parkhomenko; Pentti Põder; Gerhard Pölzl; Alexander Reinecke; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Toni Sarapohja; Robert Hg Schwinger; Wolfgang Toller; Luigi Tritapepe; Carsten Tschöpe; Gerhard Wikström; Dirk von Lewinski; Bojan Vrtovec; Piero Pollesello
Journal:  Card Fail Rev       Date:  2020-07-08

Review 8.  Levosimendan for Perioperative Cardioprotection: Myth or Reality?

Authors:  Elpidio Santillo; Monica Migale; Carlo Massini; Raffaele Antonelli Incalzi
Journal:  Curr Cardiol Rev       Date:  2018

Review 9.  Use of Levosimendan in Intensive Care Unit Settings: An Opinion Paper.

Authors:  Antoine Herpain; Stefaan Bouchez; Massimo Girardis; Fabio Guarracino; Johann Knotzer; Bruno Levy; Tobias Liebregts; Piero Pollesello; Sven-Erik Ricksten; Hynek Riha; Alain Rudiger; Fabio Sangalli
Journal:  J Cardiovasc Pharmacol       Date:  2019-01       Impact factor: 3.105

Review 10.  Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper.

Authors:  Bernard Cholley; Bruno Levy; Jean-Luc Fellahi; Dan Longrois; Julien Amour; Alexandre Ouattara; Alexandre Mebazaa
Journal:  Crit Care       Date:  2019-11-29       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.